Latch, Inc. (LTCH): Nasdaq/NYSE listing notice — Latch receives additional Nasdaq non-compliance notice for Q1 2023 filing delay

Latch, Inc.

On May 16, 2023, Latch received Nasdaq notice for failure to timely file Q1 2023 10-Q.
Nasdaq Hearings Panel will consider this failure in determining continued listing.
Company also failed to file Q2, Q3 2022 10-Qs and 2022 10-K due to restatement of 2019-2022 financials.
Compliance plan requires filing all overdue reports by August 4, 2023 to avoid delisting.
No assurances of timely filing; securities at risk of delisting from Nasdaq.

item 3.01 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Latch, Inc. received a nasdaq extension granted notice regarding late filing (rules 5250(c)(1)).

Exchange: nasdaq
Notice: extension granted
Deficiency: late filing
Rules: 5250(c)(1)

Exact text from the filing

May 16, 2023, the Company was unable to timely file its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2023 (the “First Quarter 2023 Report”) with the SEC due to the ongoing effort to restate the Company’s consolidated financial statements for 2019, 2020, 2021, and the first quarter of 2022 (all such interim and annual periods, the “Affected Periods”). The Company presented its plan to regain compliance (the “Compliance Plan”) with Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”) at a March 23, 2023 hearing before a Nasdaq Hearings Panel (the “Panel”). As set forth i

View on SEC.gov

Browse all listing & compliance notices →

Latch, Inc. filing history →

Source: SEC EDGAR

accession 0001826000-23-000060

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.